Josef Penninger

APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria.

APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria.

APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria.

APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria.

APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria.